IC51: a new investigational Japanese encephalitis vaccine

Abstract

Christoph S Klade is a biochemist and immunologist by training. He obtained his PhD from the University of Vienna (Austria) and obtained further training in immunology at the Universities of Berkeley and Stanford (CA, USA). After university, Dr Klade spent over 13 years in industrial R&D. These years included the setting up of technology platforms for identification of both B- and T-cell antigens, discovery research, assay development and validation and close involvement in clinical research. At Intercell AG, he set up the Department of Clinical Immunology, responsible for all immunological monitoring of Intercell’s vaccine trials, including T-cell and serology assays. Recently, data from this department was the basis for successful pivotal Phase III trials in the development of a novel prophylactic vaccine against Japanese encephalitis virus 1. Currently, Dr Klade serves as Vice President of Technology Development/Clinical Immunology at Intercell AG, overlooking functions such as Analytical and Formulation Development, Process Development, External Manufacturing and Clinical Immunology. In addition, Dr Klade has been appointed to lead the codevelopment of the hepatitis C virus therapeutic vaccination program of Intercell and Novartis.

Financial & competing interests disclosure

C Klade is an employee of Intercell AG. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.